ALD 401 / Nuo Therapeutics - LARVOL DELTA

A Phase 2 Randomized, Sham Controlled Trial of Internal Carotid Artery Infusion of Autologous Bone Marrow Derived ALD-401 Cells in Patients with Recent Stable Ischemic Stroke (RECOVER-Stroke). (PubMed, Circulation) - P2; "Intra-carotid infusion of ALD-401 does not lead to clinical adverse events in patients with subacute ischemic stroke although there was a higher incidence of small lesions on MRI in the treatment group. There was no difference in the primary efficacy endpoint between the groups. The study provides a frame-work for the design and conduct of future intra-arterial cell therapy trials in stroke."

Clinical • Journal • P2 data